Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vepdegestrant - Arvinas/Pfizer

Next Previous
Drug Profile

Vepdegestrant - Arvinas/Pfizer

Alternative Names: ARV-471; PF-07850327

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arvinas
  • Developer Arvinas; Pfizer
  • Class Antineoplastics; Isoindoles; Phenols; Piperazines; Piperidines; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer

Most Recent Events

  • 04 Apr 2024 Pfizer plans a phase I trial in Healthy volunteers (PO) (NCT06347861)
  • 27 Feb 2024 Pfizer in collaboration with Arvinas initiates the phase Ib/II TACTIVE-K trial in Breast Cancer (Late-stage disease, Metastatic disease, Combination therapy, Second line therapy or greater) in USA (PO), prior to February 2024 (EudraCT2023-508130-33-00) (NCT06206837)
  • 23 Feb 2024 Pfizer initiate a phase I pharmacokinetics trial in healthy volunteers (NCT06275841)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top